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stefan.knapp@sgc.ox.ac.uk (S. Knapp).e-N-acetylation of lysine residues (Kac) is one of the most abundant post-translation modiﬁcations
(PTMs) in the human proteome. In the nucleus, acetylation of histones has been linked to transcrip-
tional activation of genes but the functional consequences of most acetylation events and proteins
recruited to these sites remains largely unknown. Bromodomains (BRDs) are small helical interac-
tion modules that speciﬁcally recognize acetylation sites in proteins. BRDs have recently emerged as
interesting targets for the development of speciﬁc protein interaction inhibitors, enabling a novel
exiting strategy for the development of new therapies. This review provides an overview over
sequence requirements of BRDs, known substrates and the structural mechanisms of speciﬁc Kac
recognition.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
The concept of epigenetics was ﬁrst introduced in 1939 by
Waddington [1] to describe ‘‘the causal interactions between genes
and their products, which bring the phenotype into being’’, and
was later deﬁned as heritable changes in gene expression that
are not due to alterations in DNA sequence [2]. The physical corre-
late of these heritable changes is found in chromatin, composed of
DNA, histones and other proteins that organize DNA topology. Over
the past decade it has become increasingly clear that post-transla-
tional modiﬁcations (PTMs) of histones play a central role in regu-
lating transcription of genes. The majority of histone modiﬁcations,
sometimes referred to as ‘histone code’, are found mainly on the N-
terminal histone tails that protrude from the globular core of the
nucleosome [3] and include acetylation, methylation, phosphoryla-
tion, ribosylation, biotinylation, citruillination and SUMOylation
[4,5]. Recently also a number of further modiﬁcations such as cro-
tonylation have been described [6]. Each modiﬁcation can affect
chromatin structure, but the overall state of chromatin is ulti-
mately determined by combinations of these modiﬁcations. This
complex code of post translational modiﬁcations plays important
roles in maintaining genome integrity, regulating transcription,
and constitutes to the so called epigenetic memory, a mechanismal Societies. Published by Elsevier
.ac.uk (P. Filippakopoulos),which is poorly understood that inherits expression patterns in
dividing cells [7].2. Lysine acetylation – a prominent post translation
modiﬁcation
A discovery made more than 30 years ago revealed that e-N-
acetylation of lysine residues (Kac) on histone tails is associated
with an open chromatin architecture and transcriptional activation
[8], although certain acetylation marks have been associated in-
stead with chromatin compaction [9] and with other processes,
such as metabolism, DNA repair [10], protein–protein interaction
and protein stability [5]. Although lysine acetylation has been
studied for a long time in the context of the histone code it is
now recognized as a widespread post-translational modiﬁcation
occurring throughout the proteome [11,12]. So far, 18330 sites
on 6870 proteins have been reported in total in human cells in
the PhosphoSitePlus database (http://www.phosphosite.org) sug-
gesting a wider role for this PTM, highlighting its importance. Sur-
prisingly lysine-acetylation is also abundant in non-nuclear
proteins. Given the widespread nature of acetylation together with
the existence of enzymes that control it (acetyl-transferaces and
de-acetylases) it has been suggested that it could be compared to
phosphorylation as a regulatory mechanism for signal transduction
in cells [13]. However, in contrast to protein phosphorylation no
acetylation dependent pathways have been described but similarly
to phosphorylation, dysfunctional acetylation levels have been
linked to the development of a large number of diverse diseases.B.V. Open access under CC BY-NC-ND license. 
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often drives the aberrant expression of oncogenes resulting in pro-
liferation and tumorigenesis. As a consequence enzymes that reg-
ulate lysine acetylation in histones, such as ‘writers’ or histone
acetyltranferases (HATs), and ‘erasers’, histone deacetylases
(HDACs) have emerged as attractive cancer targets. A rich litera-
ture has been established around the beneﬁts of inhibiting Kac
‘erasing’ events on chromatin in the past decades in order to affect
gene expression, resulting in approved drugs as well as a large
number of drug candidates, currently on clinical trials, targeting
HDACs in cancer and neurodegenerative diseases such as Parkin-
son and Alzheimer [14–18]. Recently also proteins that are respon-
sible for the ‘readout’ of Kac, such as Bromodomains have emerged
as potential drug targets and have been successfully targeted by
small molecule inhibitors [19–21].3. Bromodomains – readers of lysine acetylation
‘Readers’ of epigenetic marks are structurally diverse proteins
each possessing one or more evolutionarily conserved effector
modules, which recognize covalent modiﬁcations of histone pro-
teins or DNA. Bromodomains (BRD) are the only interaction mod-
ules that speciﬁcally recognize e-N-acetylation of lysine residues.
All BRDs fold into an evolutionary conserved 120 residue struc-
tural four helix motif identiﬁed in the early 90s as a conserved
domain in the Drosophila brahma gene [22]. The human genome
encodes 46 diverse proteins that contain a total of 61 BRDs, pres-
ent in many diverse transcriptional co-regulators and chromatin
modifying enzymes, such as HATs and HAT associated proteins
(GCN5, PCAF, BRD9) [23,24], ATP-dependent chromatin-remodel-
ling complexes (BAZ1B) [25], helicases (SMARCA) [26], SET do-
main containing methyl-transferases (MLL and ASH1L) [27,28],
transcriptional co-activators (TRIM/TIF1) [29] and mediators
(TAF1) [30], nuclear scaffolding proteins (PB1) [31] and the BET
family [32] (Table 1 [33]). Their biological functions as well as
their potential as therapeutic targets have been recently reviewed
[34]. Although BRD modules exhibit large sequence variations,
they share a conserved fold that comprises a left-handed bundle
of four alpha helices (aZ, aA, aB, aC), linked by diverse loop re-
gions of variable length (ZA and BC loops), which line the Kac
binding site. Co-crystal structures with peptides demonstrated
that acetyl-lysine epitopes are recognized by a central deep
hydrophobic cavity, where the Kac is anchored by a hydrogen
bond to a conserved asparagine residue present in most BRDs
[35,36] (Fig. 1A). It is interesting to point out that the diversity
of the rim region lining up the Kac binding site determines the
surface properties thus driving binding speciﬁcity (Fig. 1B) [33].
A recent large scale structure-based analysis of the human BRD
family using 34 high resolution crystal structures and 4 NMR
models, together with secondary structure prediction algorithms,
clustered the 61 available BRD modules into eight distinct fami-
lies [33] (Fig. 1C). Brieﬂy, models (XRay and NMR) were structur-
ally superimposed and the resulting sequence alignment was
used as a template to further align sequences of BRDs of un-
known structure, using their predicted secondary structure ele-
ments as a footprint. This manually-curated sequence alignment
was then used as a seed for generating a distance matrix employ-
ing the Neighbour-joining algorithm implemented in the Clu-
stalW2 program. Given the structural conservation of the
bromodomain fold, this method clustered the modules according
to subtle differences manifested in their three dimensional struc-
ture in a similar fashion to plain sequence alignments. Impor-
tantly this method highlighted structurally conserved motifs
which can be used together with secondary structure elements
to identify new BRDs.4. Bromodomain substrates
To date there are no systematic studies that describe substrate
speciﬁcity of BRDs and only a few histone acetylation marks have
been associated with a speciﬁc BRD. In total there have been re-
ports describing usually single interactions (and in some reports
afﬁnities) for 20 out of the 46 BRD-containing proteins. In addition,
published afﬁnities of BRD substrate interactions are usually weak
and have been determined by a variety of different biophysical
techniques employing various lengths for the studied peptidic sub-
strates. Methods used for substrate identiﬁcation comprise classi-
cal pull-down experiments, peptide arrays (SPOT), biophysical
techniques such as isothermal titration calorimetry (ITC), ﬂuores-
cent polarization (FP) spectroscopy, Surface Plasmon Resonance
(SPR) and NMR. For example, the bromodomains of BRD2 have
been shown to bind acetylated histone H4 at lysine 12 (H4K12ac)
in cells [37]. A dissociation constant (KD) of 360 lM for the di-acet-
ylated substrate peptide H4K5ac/K12ac has been determined
in vitro by SPR [36] and a KD for the mono-acetylated H4K12ac pep-
tide of 2.9 mM has been determined by NMR titrations [38]. Fur-
thermore, closely spaced multiple acetylation sites have been
shown to increase afﬁnity of the H4 tail for the murine BET family
member BRDT [39] and this observation has been studied in detail
for the entire subfamily of BET proteins [33] suggesting a coopera-
tive role of neighbouring sites for substrate binding. Although
there have been reports linking BRDs to acetylation sites in pro-
teins other than histones, current research has been focussed on
histone proteins given the signiﬁcance of BRDs in chromatin biol-
ogy [34]. Lastly, despite the large number of post translation mod-
iﬁcations found on histones [5,6] studies on the effect that
combinations of these PTMs may have on binding are limited only
to a few marks.
Following the recent structure-based classiﬁcation of human
BRDs there are eight families that span all 61 domains. The ﬁrst
subfamily (I) contains the acetyl-transferase containing proteins
P300/CBP-associated factor (PCAF) [24] and the general control of
amino-acid synthesis 5-like 2 (GCN5L) [23] as well as the transcrip-
tion factor Fetal Alzheimer antigen (FALZ) [25] and the chromatin
remodelling factor cat eye syndrome chromosome region 2 (CECR2)
[40], all of which localize in the nucleus (Table 1). The solution
structure of PCAF established in the late 90s the ability of BRDs
to bind acetylayted lysine and supported the hypothesis that
BRD-containing proteins contribute to highly speciﬁc histone acet-
ylation by targeting HATs to speciﬁc chromosomal sites [24]. The
BRD of PCAF has been shown to interact in vitro with acetylated
histone H3 sites (K9ac [41], K14ac [33,41], K36ac [41]) as well as his-
tone H4 sites (K8ac [24], K16ac [33,41] and K20ac [33,41]). It has
also been shown to bind to the HIV-1 transcriptional trans-activa-
tor Tat (K50ac [41]), an interaction required to stimulate transcrip-
tion of the integrated HIV-1 genome. All PCAF/Kac interactions have
been quantiﬁed and although there are small discrepancies in the
determined afﬁnities they all fall in the low micromolar range.
The BRD of GCN5L2 has also been studied in the context of histone
binding and has been shown to interact with histone H2A (K5ac
[42]), histone H3 (K9ac, K14ac, K9ac/K14ac [43]) and histone H4
(K8ac/K14ac and K16ac [35], K5ac/K8ac/K12ac/K16ac [43]) although
the binding afﬁnities of interactions have not been quantiﬁed
yet. FALZ was shown to interact with histone H4 (K5ac [33]) as well
as a poly-arginine 11-mer peptide that carried a central acetylated
lysine epitope, demonstrating how afﬁnity for this class of modules
is mainly driven by electrostatic attractions of the rim-regions that
ﬂank the central Kac docking site. CECR2 also has afﬁnity for his-
tone H3 peptides (K9ac, K14ac, [33]) and binds to single marks even
on diacetylated peptides (K9ac/K14ac [33]). Interestingly binding to
histone H3 K9ac/K14ac was found to be attenuated by phosphoryla-
Table 1
Human BRD Containing Proteins [33].
Protein Name Alias Protein function Sub-cellular
localization1
UniProt ID Reference
ASH1L ash1 (absent, small, or homeotic)-like ASH1, KMT2H Methyltransferase N, C Q9NR48 [28]
ATAD2 Two AAA domain containing protein ANCCA Transcriptional regulator N Q6PL18 [67]
BAZ1A Bromodomain adjacent to zinc ﬁnger domain, 1A ACF1, WALp1,
WCRF180
Chromatin remodeling factor N Q9NRL2 [102]
BAZ1B Bromodomain adjacent to zinc ﬁnger domain, 1B WSTF, WBSCR9 Chromatin remodeling factor,
Transcriptional regulator
N Q9UIG0 [25]
BAZ2A Bromodomain adjacent to zinc ﬁnger domain, 2A TIP5, WALp3 Transcriptional repressor N, C Q9UIF9 [77]
BAZ2B Bromodomain adjacent to zinc ﬁnger domain, 2B WALp4 Unknown N, C Q9UIF8 [78]
BRD1 Bromodomain containing protein 1 BRL, BRPF2 Transcriptional regulator, Scaffold
protein
N, C O95696 [46]
BRD2 Bromodomain containing protein 2 FSH, RING3 Transcriptional regulator N P25440 [45]
BRD3 Bromodomain containing protein 3 ORFX, RING3L Transcriptional regulator N Q15059 [45]
BRD4 Bromodomain containing protein 4 CAP, MCAP,
HUNK1
Transcriptional regulator N O60885 [46]
BRD7 Bromodomain containing 7 BP75, NAG4,
CELTIX1
Transcriptional regulator N Q9NPI1 [65]
BRD8B Bromodomain containing 8 B SMAP, SMAP2 Transcriptional regulator N Q9H0E9-2 [55]
BRD9 Bromodomain containing 9 Unknown N, C Q9H8M2 NA
BRDT Bromodomain, testis-speciﬁc BRD6 Chromatin remodeling factor N Q58F21 [39]
BRPF1 Bromodomain and PHD ﬁnger-containing protein
1A
BR140, Peregrin Transcriptional activator N, C P55201-1 [66]
BRPF3 Bromodomain and PHD ﬁnger containing, 3 Unknown N Q9ULD4 NA
BRWD3 Bromo domain-containing protein disrupted in
leukemia
BRODL JAK-STAT signaling N, C Q6RI45 [58]
CECR2 Cat eye syndrome chromosome region Chromatin remodeling factor N Q9BXF3 [40]
CREBBP CREB binding protein CBP, KAT3A Histone acetyl transferase N Q92793 [56]
EP300 E1A binding protein p300 p300, KAT3B Histone acetyl transferase N Q09472 [56]
FALZ Fetal Alzheimer antigen BPTF, FAC1 Transcription factor N Q12830 [25]
GCN5L2 General control of amino-acid synthesis 5-like 2 KAT2A, GCN5 Histone acetyl transferase N Q92830 [23]
KIAA1240 KIAA1240 protein ATAD2B Not known N Q9ULI0 NA
LOC93349 SP140 -like SP140L Unknown U Q13342 NA
MLL Myeloid/lymphoid or mixed-lineage leukemia
(trithorax homolog, Drosophila)
HRX, TRX1,
CXXC7, ALL-1
Histone Methyl transferase N Q03164 [80]
PB1 Polybromo 1 PBRM1, BAF180 Chromatin remodeling factor N, C Q86U86 [31]
PCAF P300/CBP-associated factor KAT2B Histone acetyl transferase N Q92831 [24]
PHIP Pleckstrin homology domain interacting protein WDR11, ndrp Insulin signalling N Q8WWQ0 [59]
PRKCBP1 Protein kinase C binding protein 1 ZMYND8,
RACK7
Transcriptional regulator N Q9ULU4 [103]
SMARCA2 SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin a2
BRM, SNF2L2 Chromatin remodeling factor,
Splicing regulator
N P51531 [86]
SMARCA4 SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin a4
BRG1, SNF2L4,
SNF2LB
Chromatin remodeling factor N P51532 [87]
SP100 Nuclear auto-antigen Sp-100 Transcriptional regulator N, C P23497 [74]
SP110 Nuclear auto-antigen Sp-110 A Nuclear auto-
antigen Sp-110 C
IPR1 Transcriptional regulator N Q9HB58 [75]
SP140 SP140 nuclear body protein LYSP100 Transcriptional regulator N, C Q13342 [76]
TAF1 TAF1 RNA polymerase II, TATA box binding protein
(TBP)-associated factor
TAFII250 Transcription initiation N P21675 [83]
TAF1L TAF1-like RNA polymerase II, TATA box binding
protein (TBP)-associated factor
TAF(II)210 Transcription initiation N Q8IZX4 [84]
TIF1a Transcriptional intermediary factor 1 TRIM24, PTC6,
RNF82,
Transcriptional regulator N, C O15164 [73]
TRIM28 Tripartite motif-containing 28 KAP1, RNF96,
TIF1b
Transcriptional regulator N Q13263 [81]
TRIM33 Tripartite motif-containing 33 A PTC7, RFG7,
TIF1c
Control of Transcription elongation N Q9UPN9 [72]
TRIM66 Tripartite motif-containing 66 TIF1d Transcriptional repressor N O15016 [71]
WDR9 WD repeat domain 9 BRWD1 Chromatin remodeling factor N Q9NSI6 [57]
ZMYND11 Zinc ﬁnger, MYND domain containing 11 BS69, BRAM1 Transcriptional repressor N Q15326 [82]
1 Nuclear or Cytoplasmic.
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gression suggesting that this PTM can inﬂuence binding to the sur-
rounding acetylation marks. Notably, pS10 has also been linked to
increased HAT activity resulting in elevated levels of H3K14ac [44].
The bromo and extra terminal (BET) proteins belong to the sub-
family II of BRDs, sharing a common architecture comprising two
N-terminal BRDs that exhibit high levels of sequence conservation
as well as an extra-terminal (ET) domain and a more divergent C-
terminal recruitment domain. There are four proteins in this sub-family, BRD2 [45], BRD3 [45], BRD4 [46] and BRDT [39]. Interest-
ingly BET proteins are recruited to transcriptional start sites during
mitosis [37,47,48] and the BET protein BRD4 has been shown to
tether the positive transcription elongation factor (P-TEFb) to these
sites via its unique C-terminus. As such, their interactions with his-
tones have been studied in detail by several groups (Table 2). Most
importantly BET proteins have been shown to bind to multiple
adjacent acetyl sites with increased afﬁnity and the structural basis
of this interaction has been explained in detail in the case of the
BRD3(2)BRD2(2)
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Fig. 1. Bromodomain Overall Fold, Substrate Binding Mode and Phylogeny. (A) Overall structure of the BRD2(1) bromodomain. N-, C-termini and secondary structure
elements are labelled (PDB ID: 2DVQ, [36]). Binding of a histone H4 peptide acetylated at lysine 12 (H41-15K12ac) on the central cavity of the module is also shown. (B) Surface
of the BRD2(1) module (same orientation as in A) coloured according to its electrostatic potential as indicated in the inset, demonstrating the surface charge around the Kac
binding cavity. (C) Structure based phylogenetic tree of the human bromodomain family. The different families are named by Roman numbers (I–VIII).
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tone H4 peptides (K5ac/K8ac/K12ac/K16ac) have single digit micro-
molar afﬁnity for single or tandem BET BRDs and both
bromodomains of each BET member exhibit afﬁnity for histone
H4 peptides with single or multiple acetylations although the N-
terminal domain in each protein seems to bind with higher afﬁnity
than the C-terminal one [33,36–39,45,49]. Afﬁnity for histone H3
peptides has also been demonstrated although it appears to be sys-
tematically stronger in the case of the C-terminal domains suggest-
ing a mode of cooperativity between the tandem modules, either
binding to the same nucleosome on different histone tails at the
same time, or bridging adjacent nucleosomes by binding on his-
tone H3 of the ﬁrst and histone H4 of the second. It is however
noteworthy that deletion of the ﬁrst BRD in BRDT is sufﬁcient to
cause male sterility in mice by blocking development of mature
sperm [50]. A link between BET proteins and increased expression
of inﬂammatory genes via the transcriptional activation of NF-jB
occurs through their interaction with the acetylated RelA subunit
of NF-jB [51] as evidenced in the case of BRD4. This interaction
is of particular interest as K310 acetylation is required for full tran-
scriptional activity of RelA in the absence of effects on DNA binding
[52]. BRD3 has been shown to interact with the acetylated tran-
scription factor GATA1 recruiting this transcription factor to both
active and repressed target genes in a histone acetylation-indepen-
dent fashion [53]. The structural basis for this interaction was re-
cently investigated in solution showing that BRD3(1) is
responsible for acetylated-GATA1 association (diacetylated at ly-
sines K312 and K315) while BRD3(2) does not seem to contribute
to the interaction despite the existence of four distinct Kac sites.
A recent study also suggests that BRD4 can directly bind to P-TEFb
via interactions of its second BRD with three acetyl-lysines found
on Cyclin-T1 [54].Subfamily III of BRDs contains the transcriptional regulator
bromodomain containing 8B (BRD8B) [55], the HAT enzymes CREB
binding protein (CREBBP) and E1A binding protein p300 (EP300)
[56], the C-terminal domain of the chromatin remodelling factors
WD repeat domain 9 (WDR9 domain 2) [57], the bromodomain adja-
cent to zinc ﬁnger domain 1B (BAZ1B) [25], the C-terminal domain of
the JAK/STAT pathway related bromodomain-containing protein dis-
rupted in leukemia (BRWD3 domain 2) [58] and the C-terminal do-
main of the insulin signalling related pleckstrin homology domain
interacting protein (PHIP domain 2) [59]. Following the idea of tar-
geting enzymatic HAT activity to speciﬁc sites via recognition of
acetyl-lysine motifs, the BRDs of CREBBP and EP300 have been
extensively studied in the context of histone binding. CREBBP
binds histone H2B (K85ac [33]), histone H3 (K9ac/K14ac, K14ac,
K36ac, K56ac [33,41,60]) as well as histone H4 (K12ac, K20ac, K44ac
[33,41]). Importantly it was shown that serine 10 phosphorylation
enhances binding to H3K14ac 6-fold [33]. CREBBP has also been
shown to bind to acetylated p53 (K382ac [41]) inducing p53
acetylation-dependent coactivator recruitment after DNA damage,
leading to p53-induced transcriptional activation of the cyclin-
dependent kinase inhibitor p21. The structural basis for this inter-
action has been studied in solution [61]. Notable, the BRD of
CREBBP binds to mono- and di-acetylated myogenic transcription
factor MyoD (K99ac, K99ac/K102ac [62,63]) resulting in increased
activity on muscle speciﬁc promoters, presumably via increased
binding to DNA [64]. The BRD of EP300 also binds to acetylated
histone H3 (K36ac, K56ac [33]) and histone H4 (K12ac, K20ac,
K44ac [33]) and interestingly only binds to diacetylated MyoD
(K99ac/K102ac [63]).
Subfamily IV of BRDs contains the transcriptional regulators
bromodomain containing 7 (BRD7) [65], bromodomain containing
protein 1 (BRD1) [46], bromodomain and PHD ﬁnger-containing
Table 2
Studied BRD/Peptide Interactions.
Bromodomain Sequence Afﬁnty (lM) Method Used Ref.
ATAD2 H3K14 N/A Not quantiﬁed IP [68]
BAZ2B H3K14 KSTGGKacAPRKQY 7.6 ± 0.3 ITC [33]
BPTF H4K5 SGRGKacGGKGLY 175 ± 13.3 ITC [33]
Poly-R RRRRRKacRRRRRY 3.1 ± 0.1 ITC
BRD2(1/2) H3K14 N/A Not quantiﬁed IP [45]
H4K5 N/A Not quantiﬁed IP
H4K12 N/A Not quantiﬁed IP [37]
BRD2(1) H4K5 SGRGKacGGKGLY 130 ± 4.4 ITC [33]
H4K5/8 SGRGKacGGKacGLGY 13.5 ± 0.3 ITC
H4K5/12 SGRGKacGGKGLGKacGGA 360 SPR [36]
H4K8/12 GKacGLGKacGGAKR 65.8 ± 3.5 ITC [33]
H4K12/16 GKacGGAKacRHRKV 29.4 ± 1.0 ITC
H4K12/16/20 GKacGGAKacRHRKacV 27.9 ± 0.7 ITC
H4K5/8/12/16 YSGRGKacGGKacGLGKacGGAKacRHRK 3.7 ± 0.1 ITC
BRD2(2) H4K5/8 SGRGKacGGKacGLGY 13.5 ± 0.3 ITC [33]
H4K12 GKGLGKacGGAKR 2900 NMR [38]
H4K8/12 GKacGLGKacGGAKR 65.8 ± 3.5 ITC [33]
H4K12/16 GKacGGAKacRHRKV 29.4 ± 1.0 ITC
H4K12/16/20 GKacGGAKacRHRKacV 27.9 ± 0.7 ITC
H4K5/8/12/16 YSGRGKacGGKacGLGKacGGAKacRHRK 3.7 ± 0.1 ITC
BRD3(1/2) H3K14 N/A Not quantiﬁed IP [45]
H4K5 N/A Not quantiﬁed IP
BRD3(1) H4K8 RGKGGKacGLGKGY 211 ± 5.2 ITC [33]
H4K12/16/20 GKacGGAKacRHRKacV 31.4 ± 0.9 ITC
GATA1 K312ac/K314ac/K315ac/K316ac Not quantiﬁed IP [53]
KASGKacGKKacKRGSN Not quantiﬁed NMR [92]
KASGKacGKacKacKacRGSN 0.011 ± 0.006 NMR
BRD3(2) H3K18 GKAPRKacQLATKY 67.1 ± 4.5 ITC [33]
H4K12 GKGLGKacGGAKRY 149 ± 8.0 ITC
H4K20 AKRHRKacVLRDNY 10.5 ± 0.2 ITC
H4K12/16/20 GKacGGAKacRHRKacV 61.3 ± 1.9 ITC
BRD4(1/2) H4K5/8/12/16 YSGRGKacGGKacGLGKacGGAKacRHRK 2.7 ± 0.2 ITC [33]
RelA-K310 N/A Not quantiﬁed IP [51]
BRD4(1) H3K9 KQTARKacSTGGKY 301 ± 40.9 ITC [33]
H3K9/K14 KQTARKacSTGGKacAPRK Not quantiﬁed NMR [49]
H4K5 SGRGKacGGKGLGKGGAK 810 ± 57 NMR
H4K8 RGKGGKacGLGKGY 84.7 ± 8.2 ITC [33]
H4K12 SGRGKGGKGLGKacGGAK 650 ± 11 NMR [49]
H4K5/8 SGRGKacGGKacGLGY 6.8 ± 0.1 ITC [33]
H4K5/12 SGRGKacGGKGLGKacGGAK Not quantiﬁed NMR [49]
H4K8/12 GKacGLGKacGGAKR 27.4 ± 0.9 ITC [33]
H4K12/16 GKacGGAKacRHRKV 46.1 ± 0.9 ITC
H4K12/16/20 GKacGGAKacRHRKacV 20.4 ± 0.8 ITC
H4K5/8/12/16 YSGRGKacGGKacGLGKacGGAKacRHRK 2.8 ± 0.2 ITC
RelA-K310 N/A Not quantiﬁed IP [51]
BRD4(2) H3K14 KSTGGKacAPRKQY 260 ± 32.2 ITC [33]
H3K9/14 KQTARKacSTGGKacAPRK Not quantiﬁed NMR [49]
H4K5 SGRGKacGGKGLGKGGAK 1000 ± 126 NMR
H4K5 SGRGKacGGKGLY 60.2 ± 2.5 ITC [33]
H4K12 SGRGKGGKGLGKacGGAK 1350 ± 78 NMR [49]
H4K5/12 SGRGKacGGKGLGKacGGAK Not quantiﬁed NMR
H4K31 IQGITKacPAIRRY 170 ± 10.1 ITC [33]
H4K5/8 SGRGKacGGKacGLGY 63.3 ± 2.3 ITC
H4K8/12 GKacGLGKacGGAKR 20.4 ± 0.8 ITC
H4K12/16 GKacGGAKacRHRKV 49.3 ± 1.1 ITC
H4K12/16/20 GKacGGAKacRHRKacV 22.7 ± 0.8 ITC
H4K5/8/12/16 YSGRGKacGGKacGLGKacGGAKacRHRK 26.6 ± 0.1 ITC
RelA-K310 N/A Not quantiﬁed IP [51]
CyclinT1 K380ac/K286ac/K390ac Not quantiﬁed NMR [54]
BRDT(1) H2BK12/15 PEPSKSAPAPKKacGSKacKAISKAQ 157 ± 15 ITC [39]
H3K9/14/18/23 H3(1–27)K9acK14acK18acK23ac 390 ± 36 ITC
H4K12 GKGLGKacGGAKRY 150 ± 14.6 ITC [33]
H4K5/8 SGRGKacGGKacGLGKGGAKRHRK 21.9 ± 1.7 ITC [39]
H4K8/12 SGRGKGGKacGLGKacGGAKRHRK 193 ± 22 ITC
H4K12/16 SGRGKGGKGLGKacGGAKacRHRK 117 ± 22 ITC
H4K5/12 SGRGKacGGKGLGKacGGAKRHRK 340 ± 67 ITC
H4K5/8/12/16 SGRGKacGGKacGLGKacGGAKacRHRK 28.0 ± 6.1 ITC
H4K5/8/12/16 YSGRGKacGGKacGLGKacGGAKacRHRK 23.0 ± 0.5 ITC [33]
BRDT(2) H3K9/14/18/23 H3(1–27)K9acK14acK18acK23ac 214 ± 48 ITC [39]
H3K14/18 H3(1–27)K14acK18ac 217 ± 28 ITC
H3K18/23 H3(1–27)K18acK23ac 176 ± 52 ITC
H3K9/18 H3(1–27)K9acK18ac 360 ± 140 ITC
H3K18 H3(1–27)K18ac 251 ± 62 ITC
BRD7 H3K9 QTARKacSTGG 3960 ± 440 NMR [70]
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H3K14 STGGKacAPRK 1190 ± 20 NMR
H4K8 SGRGKGGKacGLGK 1790 ± 100 NMR
H4K12 KGLGKacGGAK 3420 ± 140 NMR
H4K16 GGAKacRHRK 2560 ± 110 NMR
CECR2 H3K9 KQTARKacSTGGKY 189 ± 11.6 ITC [33]
H3K14 KSTGGKacAPRKQY 49.3 ± 0.8 ITC
H3K9/14 KQTARKacSTGGKacAPRKQY 57.8 ± 1.9 ITC
164.5 ± 5.5
H3K9/S10/14 KQTARKacpSTGGKacAPRKQY 51.0 ± 1.8 ITC
609.8 ± 48
CREBBP H2BK85 AHYNKacRSTITSRE 66.2 ± 3.8 ITC [33]
H3K9/14 N/A Not quantiﬁed IP [60]
H3K14 KSTGGKacAPRKQY 734 ± 90.6 ITC [33]
H3K36 ATGGVKacKPHRY 71.4 ± 1.0 ITC
H3K36 APATGGVKacKPHRYRP 122 ± 9 NMR [41]
H3K56 GTVALREIRRYQKacS 21.3 ± 1.4 ITC [33]
H3K56 IRRYQKacSTELLY 13.8 ± 0.4 ITC
H3S10/K14/18 KpSTGGKacAPRKacQY 131 ± 6.5 ITC
H4K12 GKGLGKacGGAKRY 48.1 ± 1.9 ITC
H4K20 GGAKRHRKacVLRDNIQ 218 ± 13 NMR [41]
H4K20 AKRHRKacVLRDNY 41.5 ± 1.8 ITC [33]
H4K44 GGVKacRISGLI 82.0 ± 3.8 ITC
H4K44 RRGGVKacRISGLY 25.3 ± 0.6 ITC
p53K382 QSTSRHKKacLMFKTEG 187 ± 23 NMR [41]
Fl-bA-RHKKacLMFK-NHC2H5 155 ± 5 FP
MyoD-K99 N/A Not quantiﬁed IP [62]
MyoD-K99 Biotin-CLLWACKacACKRKTTN Not quantiﬁed [63]
MyoD-K99/102 Biotin-CLLWACKacACKacRKTTN Not quantiﬁed
EP300 H3K36 ATGGVKacKPHRY 109 ± 3.8 ITC [33]
H3K56 GTVALREIRRYQKacS 13.4 ± 0.5 ITC
H4K12 GKGLGKacGGAKRY 59.5 ± 1.4 ITC
H4K20 AKRHRKacVLRDNY 54.6 ± 1.3 ITC
H4K44 GGVKacRISGLI 132 ± 6.3 ITC
MyoD-K99/K102 Biotin-CLLWACKacACKacRKTTN Not quantiﬁed [63]
GCN5 H2AK5 SGRGKacQGGKARAKAKTRSSR Not quantiﬁed NMR [42]
H3K9 N/A Not quantiﬁed IP [43]
H3K14 N/A Not quantiﬁed IP
H3K9/K14 N/A Not quantiﬁed IP
H4K8/16 AKacRHRKVLRDNIQGITKPAI 900 NMR [35]
H4K16 AKacRHRKILRNSIQGI Not quantiﬁed NMR
H4K5/8/12/16 N/A Not quantiﬁed IP [43]
KIAA1240 H4K5 N/A Not quantiﬁed IP [69,75]
H4K5 RGKGGKacGLGKGY 150 ± 6.4 ITC [33]
PB1 (all 6 single domains) H3K4 ARTKacQTARKSTGGKAPRKQLATKAA 1.1 – 34 FA [91]
H3K9 ARTKQTARKacSTGGKAPRKQLATKAA
H3K14 ARTKQTARKSTGGKacAPRKQLATKAA
H3K18 ARTKQTARKSTGGKAPRKacQLATKAA
H3K23 ARTKQTARKSTGGKAPRKQLATKacAA
PB1(1) H3K4 ARTKacQTARKSTGGKAPRKQLATKAA 0.39 FP [90]
PB1(2) H3K9 ARTKQTARKacSTGGKAPRKQLATKAA 0.36 FP
PB1(3) H3K9 ARTKQTARKacSTGGKAPRKQLATKAA 0.71 FP
PB1(4) H3K23 ARTKQTARKSTGGKAPRKQLATKacAA 0.12 FP
PB1(5) H3K14 ARTKQTARKSTGGKacAPRKQLATKAA 0.79 FP
PCAF H3K9 RTKQTARKacSTGGKAP 1051 ± 90 NMR [41]
H3K14 ARKSTGGKacAPRKQLA 128 ± 12 NMR
H3K14 KSTGGKacAPRKQY 188 ± 14.6 ITC [33]
H3K36 APATGGVKacKPHRYRP 402 ± 93 NMR [41]
H4K8 SGRGKGGKacGLGK 346 ± 54 NMR [24]
H4K16 GLGKGGAKacRHRKVLR 365 ± 10 NMR [41]
H4K16 GKGGAKacRHRKVY 103 ± 11.2 ITC [33]
H4K20 GGAKRHRKacVLRDNIQ 247 ± 53 NMR [41]
H4K20 AKRHRKacVLRDNY 90.9 ± 9.6 ITC [33]
TATK50 LGISYGRKacKRRQRRA 84 ± 12 NMR [41]
Fl-GGGGSYGRKacKRRQRC 212 ± 17 FP
SMARCA2 H3K9 N/A Not quantiﬁed IP [43]
H3K14 N/A not quantiﬁed IP
H3K14 KSTGGKacAPRKQY 287 ± 35.2 ITC [33]
H3K9/14 N/A Not quantiﬁed IP [43]
H4K8 N/A not quantiﬁed IP
H4K12 N/A Not quantiﬁed IP
H4K16 GKGGAKacRHRKVY 86.2 ± 3.0 ITC [33]
H4K5/8/12/16 N/A Not quantiﬁed IP [43]
SMARCA4 H2BK5 SDPAKacSAPAPKK Not quantiﬁed NMR [88]
H3K14 KSTGGKacAPRK 1200 NMR
H3K9/14 N/A Not quantiﬁed IP [60]
(continued on next page)
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H3K9/14 TKQTARKacSTGGKacAPR 500 NMR [89]
H4K8 SGRGKGGKacGLGK 4000 NMR [88]
H4K12 GKGLGKacGGAKR 3600 NMR
H4K16 GGAKacRHRK Not quantiﬁed NMR
H4K16 AKacRHRKVLRDNIQGI Not quantiﬁed NMR [89]
TAF1(1/2) H3K14 KSTGGKacAPRKQY 178.9 ± 6.4 ITC [33]
H3K14 N/A Not quantiﬁed IP [37]
H3K9/14 KQTARKacSTGGKacAPRKQY 339 ± 21 ITC [33]
H3K9/S10/14 KQTARKacpSTGGKacAPRKQY 150 ± 87 ITC
H4K8 N/A Not quantiﬁed IP [37]
H4K12 N/A Not quantiﬁed IP
H4K16 N/A Not quantiﬁed IP
H4K16 H4(1–36)K16ac 39 ± 7 ITC [30]
H4K8/16 H4(1–36)K8acK16ac 5.6 ± 0.2 ITC
H4K5/12 H4(1–36)K5acK12ac 1.4 ± 0.3 ITC
H4K5/8/12/16 H4(1–36)K5acK8acK12acK16ac 5.3 ± 0.2 ITC
p53K373/382 p53(364–389)K373acK382ac Not quantiﬁed IP [85]
TAF1(2) H3K14 KSTGGKacAPRKQY 306 ± 21.4 ITC [33]
TIF1a (BRD) H3K9 ARTKQTARKacSTGGKAPRKQL 232 ± 33 ITC [73]
H3K14 ARTKQTARKSTGGKacAPRKQ 229 ± 32 ITC
H4K16 GKGGAKacRHRKVY 92.6 ± 1.9 ITC [33]
TIF1a (PHD/BRD) H3K23 H3(13–32)K23ac 8.8 ± 0.1 ITC [73]
H3K27 H3(13–32)K27ac 206 ± 44 ITC
H4K16 SGRGKGGKGLGKGGAKacRHRK 26 ± 2 ITC
H3K4 H3(1–33)K4 1.4 ± 0.3 ITC
H3K4/K23 H3(1–33)K4/K23ac 0.07 ± 0.01 ITC
H3K4/K23 H3(1–33)K4me3K23ac 0.34 ± 0.04 ITC
TRIM33A (PHD/BRD) K3K9 H3(1–28)K9me3 0.20 ± 0.03 ITC [79]
H3K18 H3(1–28)K18ac 0.21 ± 0.02 ITC
H3K9/K18 H3(1–28)K9me3K18ac 0.06 ± 0.01 ITC
H3K14/18/23 H3(1–28)K9me3K14acK18acK23ac 0.20 ± 0.03 ITC
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(ATAD2) [67] as well as the KIAA1240 protein (KIAA1240) the brom-
odomain containing 9 (BRD9) and the bromodomain and PHD ﬁnger-
containing protein 3 (BRPF3). BRDs of this family have not been
extensively studied for binding to acetylated proteins although
their involvement in disease has been described and their target
sites will contribute to better understanding of their function
[34]. The BRD of ATAD2 has been shown to immunoprecipitate his-
tone H3 (K14ac [68]) but this interaction has not been quantiﬁed
yet, while the closely homologous KIAA1240 binds to histone H4
(K5ac [33,69]). Solution binding experiments have established
weak micromolar binding of the BRD of BRD7 to histone H3
(K9ac, K14ac [70]) as well as histone H4 (K8ac, K12ac, K16ac [70]).
Subfamily V of the human BRDs contains the transcriptional
repressor tripartite motif-containing 66 (TRIM66) [71], the tripartite
motif-containing 33 (TRIM33) [72], the transcriptional regulator
transcriptional intermediary factor 1 (TIF1a) [73], the transcriptional
regulators nuclear auto-antigen Sp-100 (SP100) [74], nuclear auto-
antigen Sp-110 (SP110) [75] and SP140 nuclear body protein
(SP140) [76] as well as the SP140-like protein (LOC93349), the tran-
scriptional repressor bromodomain adjacent to zinc ﬁnger domain 2A
(BAZ2A) [77] and the bromodomain adjacent to zinc ﬁnger domain
2B (BAZ2B) [78]. The main characteristic of this sub-class of brom-
odomains is the existence of a PHD/BRD tandem module which
seems to be a necessary structural motif for peptide recognition
as well as protein stability [73,79]. The BRD of TIF1a binds acety-
lated histone H3 peptides with weak micromolar afﬁnity which
is enhanced when longer peptides and the tandem PHD/BRD mod-
ule are used, suggesting a cooperativity between modules even
though peptides may not be methylated in order to promote bind-
ing to the PHD ﬁnger [73]. It is noteworthy that a monoacetylated
histone H3 peptide (K23ac) spanning residues 1–28 binds with
double digit nM afﬁnity to the PHD/BRD tandem module of TIF1a.
This observation suggests a binding mode which most likely in-
volves peptide interactions with the charged surface of the protein.
TIF1a also binds to histone H4 (K16ac [33]). The PHD/BRD tandemmodules of TRIM33A have also recently been shown to bind with
sub-micromolar afﬁnities to acetylated and poly-acetylated his-
tone H3 peptides although a trimethylated peptide spanning resi-
dues 1–28 was also shown to bind with similar afﬁnity suggesting
that the charge neutralization of lysine upon acetylation might be
overcome by surface interactions with the extended interface pre-
sented to the substrate [79]. A single digit micromolar afﬁnity for
histone H3 (K14ac) has also been reported for the BRD of BAZ2B
while the unacetylated peptide did not interact with the BRD [33].
No acetyl lysine mediated interactions with histones or other
proteins have been reported for the BRDs of subfamily VIwhich in-
cludes the histone methyl-transferase myeloid/lymphoid or mixed-
lineage leukemia (MLL) [80] and the transcriptional co-regulator tri-
partite motif-containing 28 (TRIM28) [81].
Subfamily VII of the human BRDs contains the transcriptional
repressor zinc ﬁnger MYND domain containing 11 protein
(ZMYND11) [82], the transcription initiators TAF1 RNA polymerase
II TATA box binding protein (TBP)-associated factor (TAF1) [83] and
TAF1-like RNA polymerase II TATA box binding protein (TBP)-associ-
ated factor (TAF1L) [84] and the N-terminal BRDs of the chroma-
tin remodelling factors WD repeat domain 9 (WDR9 domain 1)
[57], the JAK/STAT pathway related bromodomain-containing pro-
tein disrupted in leukemia (BRWD3 domain 1) [58] and the insulin
signalling related pleckstrin homology domain interacting protein
(PHIP domain 1) [59]. TAF1 is of particular interest as it was
the ﬁrst reported structure of a tandem BRD module which dem-
onstrated the ability of the modules to cooperatively bind to mul-
tiple Kac marks on histone H4 with low micromolar afﬁnity (K8ac/
K16ac, K5ac/K12ac, K5ac/K8ac/K12ac/K16ac [30]) although binding to
single histone H4 marks has also been reported (K8ac, K12ac,
K16ac [37]). Histone H3 binding has also been demonstrated
(K14ac [37], K9ac/K14ac [33]) and interestingly phosphorylation
of serine 10 doubles the afﬁnity of the BRD for the target peptide
[33]. TAF1 has also been shown to bind di-acetylated p53
(K373ac/K382ac [85]) resulting in recruitment to the p21
promoter.
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Fig. 2. Peptide Binding Modes and Module Cooperativity. (A) Binding of a single Kac (H4K12ac) onto BRD2(1) [36]. Key interacting residues and secondary structure elements
are labelled. (B) Co-operative binding of two Kac marks (H4K5acK8ac) onto BRD4(1) [33]. Key interacting residues and secondary structure elements are labelled. (C) Binding of
a single Kac peptide (H4K12ac) to the PHD/BRD tandem module of BPTF [93]. The arrangement of the two modules suggests a non-cooperative mode of peptide binding
between them. (D) Binding of a tri-methylated and acetylated peptide (H3K9me3K14ac) to the tandem PHD/BRD modules of TRIM33 [79]. The two modules cooperatively bind
the peptide demonstrating an avidity effect. (E) Binding of a diacetylated H4 peptide (H4K8acK12ac) to two distinct BRD4(1) BRD modules [33], suggesting that the linker
length between marks can allow for more than one BRD modules to bind the same peptide. (F) Structures of the tandem BRD modules of TAF1 [30,33] demonstrating the
ﬂexibility of the linker region which can allow for distant marks to be recognized by the tandem domains. Secondary structure elements have been annotated for the second
domain (TAF1(2)) which exhibits a different orientation between the two structures.
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methyl-transferase ash1 (absent, small, or homeotic)-like (ASH1L)
[28], the chromatin remodelling factors SWI/SNF-related matrix-
associated actin-dependent regulator of chromatin a2 (SMARCA2)
[86] and SWI/SNF-related matrix-associated actin-dependent regula-
tor of chromatin a4 (SMARCA4) [87] as well as the Polybromo 1
(PB1) [31]. The BRD of SMARCA2 has been shown to bind to histone
H3 (K9ac [43], K14ac [33,43] and K9ac/K14ac [43]) as well as histone
H4 (K8ac, K12ac [43], K16ac [33] and K5ac/K8ac/K12ac/K16ac [43]).
SMARCA4 has been reported to bind histone H2B (K5ac [88]), his-
tone H3 (K14ac [88], K9ac/K14ac [60,89]) as well as histone H4
(K8ac & K12ac [88], K16ac [88,89]). BRDs of the PB1 protein have
also been shown to bind to any of the N-terminal histone H3 lysine
marks (K4ac, K9ac, K14ac, K18ac, K23ac [90,91]) employing long pep-
tides (residues 1–25) and ﬂuorescent polarization or ﬂuorescent
anisotropy. It is noteworthy that these results could not be con-
ﬁrmed by isothermal titration calorimetry employing shorter pep-
tides (11-mers with a central Kac epitope) [33].
Given the wide distribution of acetylation in cells according
to proteomics data analysis [11] it is surprising that mainlyinteractions between histones and BRDs have been extensively
studied so far. There is evidence of interactions between BRDs
and other ‘hotspots’ such as p53 [41,85] or transcription factors
such as MyoD [62,63], RelA [51] and GATA1 [53,92]. Systematic
studies are also lacking and reported afﬁnities do not always agree
between reports especially since multiple techniques have been
used to determine binding as well as peptides of different sizes
have been employed. Studies on the cross-talk between PTMs are
also lacking although there is evidence that they affect binding,
as seen by the effect of phosphorylation of serine 10 on histone
H3 binding to the BRDs of CECR2, CREBBP and TAF1 [33]. A list of
all studied BRD/Kac interactions is given in Table 2.
5. Peptide binding modes and module cooperativity
The interactions of histones with almost half of the human BRD
family have been studied but the structural basis of these interac-
tions is limited, especially in light of their organization within large
modular proteins that have a variety of domains that can facilitate
or inhibit interactions with the target substrates. The readout of
Table 3
Structures of BRD/peptide complexes.
Protein PDB code Reso. [Å] Histone mark Peptide/ligand Ref.
BPTF 2RI7 1.45 H3K4 H3(1–9)K4me2 [104]
BPTF 2F6J 2.00 H3K4 H3(1–15)K4me3 [104]
BPTF 2FSA 1.90 H4K4 H3(1–15)K4me2 [104]
BPTF 3QZV 2.00 H4K12 H4(7–17)K12ac [93]
BPTF 3QZS 1.80 H4K16 H4(12–21)K16ac [93]
BPTF 3QZT 1.50 H4K20 H4(16–25)K20ac [93]
BRD2(1) 2DVQ 2.04 H4K12 SGRGKGGKGLGKacGGA [36]
BRD2(1) 2DVR 2.30 H4K12 GGKGLGKacGGA [36]
BRD2(2) 2E3K 2.30 H4K5/K12 SGRGKacGGKGLGKacGGA N/A
BRD3(1) 2L5E NMR GATA1-K312K315 KASGKacGKKacKRGSN [92]
BRD4(1) 3MUK 1.75 H3K23prop ATKpropAARK [105]
BRD4(1) 3MUL 1.65 H3K14buty GKbut [105]
BRD4(1) 3UVW 1.49 H4K5K8 SGRGKacGGKacGLGY [33]
BRD4(1) 3UVX 1.91 H4K12K16 GKacGGAKacRHRKV [33]
BRD4(1) 3UVY 2.02 H4K16K20 AKacRHRKacVLRDN [33]
BRD4(1) 3UW9 2.37 H4K8K12 GKacGLGKacGGAKR [33]
CREBBP 1JSP NMR p53K382 SHLKSKKGQSTSRHKKacLMFK [61]
MLL 3LQI 1.92 H3K4 H3(1–9)K4me2 [106]
MLL 3LQJ 1.90 H3K4 H3(1–9)K4me3 [106]
PB1(2) 2KTB NMR H3K14 ARTKQTARKSTGGKacAPRKQL [107]
PCAF 2RNW NMR H3K9 ARTKQTARKacSTGGKA [41]
PCAF 2RNX NMR H3K36 STGGVKacKPHRYKC [41]
PCAF 2RNY NMR H4K20 GGAKRHRKacVLRDNIQ [41]
PCAF 1JM4 NMR HIV/Tat SYGRKacKRRQR [108]
TIF1a 3O34 1.90 H3K23 H3(13–32)K23ac [73]
TIF1a 3O35 1.76 H3K27 H3(23–31)K27ac [73]
TIF1a 3O36 1.70 H4K16 H4(14–19)K16ac [73]
TIF1a 3O37 2.00 H3K4 H3(1–10)K4ac [73]
TRIM33A 3U5N 1.95 H3K14 H3(1–20)K9me3K14ac [79]
TRIM33A 3U5O 2.70 H3K14K18 H3(1–22)K9me3K14acK18ac [79]
TRIM33A 3U5P 2.80 H3K14K18K23 H3(1–28)K9me3K14acK18acK23ac [79]
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structural motif has been demonstrated by high resolution crystal
structures. A central hydrophobic cavity is presented to the peptide
substrate, which docks via a hydrogen bond to the conserved
asparagine residue found in most BRDs, with extensive back-bone
hydrogen bonding stabilizing further the BRD/peptide interaction
(Fig. 2A). However some BRDs contain a tyrosine, threonine or glu-
tamate instead of an argentine suggesting a different mode of
interaction with peptidic substrates which remains to be eluci-
dated [33]. It has also been recognized that multiple acetylations,
especially when they are closely spaced, may affect binding by
enhancing afﬁnity and this has also been structurally demon-
strated in several cases [33,39,92]. The interaction of the diacety-
lated peptides is similar to the mono-acetylated ones, with one
Kac docking directly to the conserved asparagine and the second
stabilizing it by direct hydrogen bonding to the peptide backbone,
resulting in an orientation which sterically ﬁts within the BRD cav-
ity (Fig. 2B).
As part of larger multi-domain proteins, BRDs are usually found
in tandem with a PHD module or another BRD module [33]. This
suggests a functional arrangement whereby both domains can
act in concert in order to bind to a speciﬁc acetylated site. It is still
possible that there are no interactions between the modules of the
tandem organization, as seen for example in the case of the com-
plex of BPTF and an H4K12ac peptide [93], either because the linker
between domains is not ﬂexible or because the peptide presented
is not long enough to span both modules (Fig. 2C). Interactions
however between longer peptides and a PHD/BRD module have
been reported and it is noteworthy that the afﬁnity for such sub-
strates is higher suggesting an avidity effect between modules
[73,79]. The structure of TRIM33 with a methylated and acetylated
histone H3 peptide (H3K9me3K14ac) [79] for example showed such
an interaction, whereby the tri-methylated lysine 9 binds to the
PHD module and the acetylated lysine 14 binds to the BRD module(Fig. 2D). The linker sequence between Kac marks can also affect
binding to multiple BRDs suggesting that distant marks can be rec-
ognized by two different domains in a tandem BRD/BRD system
when the linker between modules is ﬂexible or long enough to al-
low for such an organization to take place. The structure of
BRD4(1) with a histone H4 diacetylated peptide (H4K8acK12ac)
demonstrated that two distinct BRD modules can bind at the two
sites simultaneously [33] (Fig. 2E). Although the initially obtained
crystal structure of the tandem TAF1 BRDs [30] showed the two
modules in close proximity, a recent crystal structure [33] demon-
strated the ﬂexibility of the tandem system whereby one of the
two domains can move in a twist motion away from the other,
potentially allowing for longer substrates to be recognized, with
Kac marks at distant sites (Fig. 2F). A list of known BRD/peptide
structures is given in Table 3.
A superimposition of the known BRD structures found in the
public domain to the structure of BRD4(1) in complex with the
diacetylated histone H4 peptide H4(1–11)K5acK8ac (PDB ID: 3UVW
[33]) suggests that several members of other subfamilies can bind
to similar multiply acetylated motifs (Fig. 3). This suggests that the
Kac recognition cavities can be large enough to accommodate two
marks, an observation that can be exploited for the development
of speciﬁc inhibitors for this class of reader modules.
6. Inhibition of BRD-speciﬁc Kac readout
Disruption of the interaction between a BRD and its acetylated-
lysine substrates could in principle provide an additional control
over the disease-associated acetylome, when combined with HDAC
inhibitors. The deep and relatively hydrophobic cavity where Kac
epitopes dock offers a drugable pocket for the development of
small molecule inhibitors of the BRD interaction with acetylated
proteins [94]. Additionally, the diversity of the loop regions sur-
rounding the central cavity results in large variations in surface
VIII 
VII VI 
V IV 
III 
II 
I 
PB1(2)
3HMF
PB1(3)
3K2J
PB1(4)
3TLP
PB1(5)
3G0J
ASH1L
3MQM
PB1(1)
3IU5
SMARCA4
3UVD
PB1(6)
3IU6
SMARCA2B
2DAT
TAF1(1)
3UV5
TAF1(2)
3UV4
TAF1L(2)
3HMH
MLL
3LQH
TRIM28
2RO1
TIF1α
2YYN
BAZ2B
3G0L
BRD1
3RCW
BRPF1B
2D9E
ATAD2
3DAI
KIAA1240 
BRD7
2I7K
BRD9
3HME
PHIP(2)
3MB3
WDR9(2)
3Q2E
CREBBP
3DWY
EP300
3I3J
BRD2(1)
1X0J
BRD3(1)
2NXB
BRD4(1)
2OSS
BRDT(1)
2RFJ
BRD2(2)
2DVW
BRD3(2)
2OO1
BRD4(2)
2OUO
mBRDT(2)
CECR2
3NXB
FALZ
3UV2
GCN5L2
3D7C
PCAF
3GG5
Fig. 3. Double Acetylated Lysine Binding onto BRDModules. Superimposition of known holo-BRD structures (represented as white surfaces) to the complex of BRD4(1) with a
diacetylated H4 peptide (H4K5acK8ac) suggests that several BRDs can bind two Kac marks at the same time. Residues that clash with the peptide backbone are coloured in red
showing that several BRDs cannot recognize di-acetyl marks in this mode.
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possible [33]. Early BRD inhibitors with low micromollar afﬁnities
have been shown to disrupt the interaction of PCAF to the HIV-1
TAT with selectivity over the BRDs of CREBBP and TIF1b [95] or
the interaction between CREBBP and p53 [96]. Interestingly thelatter still functions effectively in cellular systems in modulating
p53 transcriptional activity by suppressing recruitment of CREBBP
to p53, ultimately leading to transcriptional activation of target
genes such as the cell cycle inhibitor p21. The BRD of CREBBP
has also been targeted by ischemin, a sulfonic acid based scaffold
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damage by down-regulating p53-induced apoptosis instigated by
doxorubicin treatment of rat cardiomyocytes [95]. Cyclic peptides
were also shown to disrupt binding of the CREBBP BRD to acety-
lated p53, thus inhibiting transcriptional activity and promoting
p53 instability in colorectal carcinoma cells [97].
Benzo- and thieno-diazepines were initially reported in the pat-
ent literature as very potent and selective inhibitors of the BET
subfamily of BRDs [98], leading us and others to investigate these
promising chemotypes. We found that benzo-diazepine and ben-
zo-triazepine scaffolds exhibit afﬁnity for BET BRDs providing good
starting points for rational inhibitor design [99]. We developed a
cell-permeable and potent inhibitor (JQ1), based on a triazolo-thi-
eno-diazepine scaffold with high afﬁnity and selectivity for all BET
BRDs [19]. Binding of JQ1 to the tandem bromodomains of BRD4
was shown to be Kac competitive and displaced BRD4 from
chromatin in human cells. Competitive binding of JQ1 to the
BRD4-NUT fusion oncoprotein in NUT-midline carcinomas (NMCs)
resulted in squamous differentiation exhibiting speciﬁc anti-
proliferative effects both in BRD4-dependent cell lines as well as
in patient-derived xenograft models. Additionally, JQ1 was shown
to have therapeutic effects in multiple myelomas, through regula-
tion of the Myc oncogenic driver in these tumors [100]. Another
benzodiazepine scaffold (IBET) was shown to exhibit great poten-
tial as an anti-inﬂammatory agent, by reducing expression of
pro-inﬂammatory genes in activated macrophages [20].
A series of weak Kac mimetic inhibitors based on the isoxazole
chemical fold has also been recently developed for BET BRDs
[101]. This acetyl lysine mimetic scaffold has also been further
optimized to yield the highly potent and speciﬁc BET inhibitor
I-BET151 which also showed improved pharmacokinetics when
compared to earlier benzodiazepines such as IBET and JQ1, exhib-
iting good efﬁcacy against human and murine acute leukaemic
cell lines, through the induction of early cell cycle arrest and
apoptosis [21]. The developed chemical molecules provide excel-
lent tools for proof-of-concept studies in different disease back-
grounds. It will be now interesting to see if molecules of similar
selectivity and potency can be developed for bromodomains out-
side the BET family.
BRD modules are part of larger multi-modular proteins and
therefore it will be interesting to see how inhibitors targeting
either single or combination of different modules will attenuate
the overall protein function. For instance, PHD ﬁngers are often
found next to BRD modules and have been shown to contribute
to increased afﬁnity for peptide substrates in vitro. Inhibition of
both the PHD and BRD function would completely abolish these
interactions while inhibition of only one module would only de-
crease binding to one speciﬁc mark. One can envision cases where
inhibitors of different functions (reading/writing/erasing of PTMs)
could be combined in order to attenuate the overall protein behav-
iour. Furthermore, when binding sites are aligned one can envision
larger molecules that could potentially bind to multiple sites at the
same time, thus abolishing the readout of PTMs altogether.
7. Outlook
The availability of sequence data of the entire human genome
made it possible to identify all members of large protein families.
The bromodomain interaction module represents a large super-
family of functional acetyl lysine interaction domains that is pres-
ent in a large diversity of proteins. High throughput
crystallography enabled rapid generation of high resolution struc-
tural models and the BRD family is now well characterized from a
structural biology viewpoint. However, so far only few substrates
have been identiﬁed in particular for non-histone proteins thatwould allow functional annotation of BRDs. The large number of
described acetylation sites and the importance of cross talk with
neighbouring post translational modiﬁcation makes systematic
peptide array studies time consuming and expensive. Proteomic
approaches may help to address the question of substrate recogni-
tion in a more effective way. These methods would also consider
the multi-domain architecture of most BRD containing proteins
which will contribute to the high afﬁnity recognition of substrates.
We believe that speciﬁc and potent BRD inhibitors will be the most
effective tools to investigate the cellular functions of bromodomain
proteins and their role in disease. Initial studies already indicated a
large potential of BRD inhibitors for the development of new treat-
ment strategies that target epigenetic reader domains.
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